Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients with advanced NSCLC treated with nivolumab. Plasma o...

Descrición completa

Detalles Bibliográficos

Principais autores:	Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2018-08-01
Series:	OncoImmunology
Assuntos:	nivolumab non-small cell lung cancer plasma pd-l1 pd-l2 granzyme b interleukine-2 interferon-γ microrna biomarker
Acceso en liña:	http://dx.doi.org/10.1080/2162402X.2018.1452581
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!